Literature DB >> 7363531

Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.

A Somogyi, H G Rohner, R Gugler.   

Abstract

The pharmacokinetics and bioavailability of cimetidine after 200 mg given intravenously and orally was studied in 6 gastric and 6 duodenal ulcer patients aged between 28 and 64 years. There were no differences in any of the pharmacokinetic parameters between the two ulcer groups, but there was considerable variation which was mainly age-related. Bioavailability was not complete, but was about 60% based on the plasma concentration data. The volume of distribution at steady-state was about 80% of body weight, and the plasma clearance value of 495 ml/min was mainly due to renal clearance (293 ml/min). The elimination half-life was approximately 2 hours. These pharmacokinetic parameters together with the percentage of dose excreted unchanged in urine following intravenous administration were all highly age correlated; all decreasing with age except the elimination half-life which increased with age. Of clinical importance is the finding that the time for which the plasma concentration exceeded 0.5 microgram/ml following oral administration was also highly age-dependent, increasing by more than 2-fold in the elderly (53 to 64y) compared with the younger (28 to 45y) patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363531     DOI: 10.2165/00003088-198005010-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

Review 3.  Drug therapy: Cimetidine.

Authors:  W Finkelstein; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

4.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

5.  Mental confusion and cimetidine.

Authors:  A C Flind; D Rowley-Jones
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

6.  Bioavailability of cimetidine in man.

Authors:  S S Walkenstein; J W Dubb; W C Randolph; W J Westlake; R M Stote; A P Intoccia
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

7.  Cimetidine and mental confusion.

Authors:  J C Delaney; M Ravey
Journal:  Lancet       Date:  1977-09-03       Impact factor: 79.321

Review 8.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 9.  Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-02       Impact factor: 9.546

10.  Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.

Authors:  J J Schentag; F B Cerra; G Calleri; E DeGlopper; J Q Rose; H Bernhard
Journal:  Lancet       Date:  1979-01-27       Impact factor: 79.321

View more
  35 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  Prescription monitoring of drug dosages in the county of Jämtland and Sweden as a whole in 1976, 1982 and 1985.

Authors:  A Wessling; G Boëthius; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs.

Authors:  V Mummaneni; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

5.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

6.  Cimetidine pharmacokinetics and dosage requirements in children.

Authors:  A Somogyi; M Becker; R Gugler
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

7.  Effect of cimetidine on digoxin disposition in peptic ulcer patients.

Authors:  M Garty; G Perry; H Shmueli; D Ilfeld; G Boner; S Pitlik; J Rosenfeld
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Cimetidine dosage regimen for patients with renal failure and for geriatric patients.

Authors:  W A Ritschel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults.

Authors:  J A Ziemniak; B M Assael; R Padoan; J J Schentag
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.